Get started
Author

Roberta K Hanna

Observed names: R Hanna, R K Hanna, Roberta Hanna, Roberta Hanna,
OpenAlex ID: A5031247910
Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis.
1996 · L W Moreland, G Margolies, et al. · PubMed · 215
The Soluble Form of IL-1 Receptor Accessory Protein Enhances the Ability of Soluble Type II IL-1 Receptor to Inhibit IL-1 Action
2003 · Dirk E. Smith, Roberta Hanna, et al. · Immunity · 182
PDF
The Pharmacokinetics of Etanercept in Healthy Volunteers
2000 · Joan M Korth-Bradley, Abbe Sue Rubin, et al. · Annals of Pharmacotherapy · 153
Human cutaneous allergic late-phase response is inhibited by soluble IL-1 receptor.
1994 · M F Mullarkey, K M Leiferman, et al. · The Journal of Immunology · 62
The pharmacokinetics of etanercept in patients with heart failure
2001 · Ozlem Soran,, Arthur M Feldman,, et al. · British Journal of Clinical Pharmacology · 19
PDF
A comparison of effects on reproduction and neonatal development in cynomolgus monkeys given human soluble IL-4R and mice given murine soluble IL-4R
2009 · Linda L. Carlock, Laine A. Cowan, et al. · Regulatory Toxicology and Pharmacology · 18
A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia
1999 · Steven H. Bernstein, Joseph Fay, et al. · Cancer Chemotherapy and Pharmacology · 14
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy
1997 · Wayne L. Furman, John H. Rodman, et al. · Cancer Chemotherapy and Pharmacology · 1
The Pharmacokinetics of Etanercept in Healthy Volunteer
2000 · Joan M Korth-Bradley, Abbe Sue Rubin, et al. · Annals of Pharmacotherapy
Works count: 9
Citation count: 664
H-index: 7
I10-index: 7
Year
Topic
Type